Genmab assumes full ownership of acasunlimab
The decision comes as BioNTech has chosen not to participate further in the programme under the existing collaboration agreement. Despite this change, Genmab will still be required to
The US Food and Drug Administration (FDA) has approved Purdue Pharma’s new drug application for Zurnai, the first nalmefene hydrochloride auto-injector, designed for the emergency treatment of opioid overdose.
Ackermans & van Haaren spearheaded the investment round, with participation from both new investors including Driehaus Capital Management and Quest for Growth. Current investors namely BioGeneration Ventures, Capricorn